Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003601 · ClinicalTrials.gov registry record · Phase 2

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 2
Development phase
38
Enrollment target

NCT00003601 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 38 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003601, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
38 participants
Enrollment target

Study Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of tretinoin and/or fenretinide may be an effective way to prevent the recurrence or further development of dysplastic nevus syndrome. PURPOSE: Randomized phase II trial to compare the effectiveness of tretinoin with or without fenretinide in treating patients with dysplastic nevus syndrome.

Interventions

  • DRUG tretinoin
  • DRUG fenretinide

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 1999-02-23
Est. Completion 2004-03-02
Phase Phase 2

Sponsor

Eastern Cooperative Oncology Group

141 total trials

What the Registry Record Tells You About NCT00003601

The ClinicalTrials.gov registry entry for NCT00003601 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which tretinoin is the first listed.

NCT00003601 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00003601 about?

NCT00003601 is a clinical study titled "Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of tretinoin and/or fenretinide may be an effective way to prevent the recurrence or further development of dysplastic nevus syndrome. PURPOSE: Randomized phase II trial...

What is the current status of trial NCT00003601?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 1999-02-23. Estimated completion is 2004-03-02.

What interventions are being tested in trial NCT00003601?

The interventions under investigation include: tretinoin (DRUG), fenretinide (DRUG).

Who is sponsoring clinical trial NCT00003601?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.